Novavax, Inc. (NVAX) reported results of the initial cohort of COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza Phase 3 trial that showed both the COVID-19-Influenza Combination and flu vaccine candidates induced immune responses similar to licensed comparators Nuvaxovid and Fluzone HD, respectively.
"Both our combination and stand-alone flu vaccine candidates induced robust immune responses and were well tolerated. This data set adds to findings from our Phase 2 trial and will help inform discussions with potential partners," said Ruxandra Draghia-Akli, Executive Vice President and Head of Research and Development, Novavax.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.